BETATREX (betamethasone valerate) by Merck & Co. is clinical pharmacology: topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. Approved for atopic dermatitis, hand eczema, psoriasis. First approved in 1983.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
BETATREX is a topical corticosteroid cream containing betamethasone valerate, approved since 1983 for inflammatory skin conditions including atopic dermatitis, hand eczema, and psoriasis. It works through anti-inflammatory, antipruritic, and vasoconstrictive mechanisms that reduce skin inflammation and itching. Absorption varies based on skin integrity, vehicle formulation, and use of occlusive dressings, with metabolism occurring primarily in the liver and renal excretion.
This legacy product approaching loss of exclusivity will likely see declining team resources and shifted focus toward generic transition management or portfolio optimization initiatives.
CLINICAL PHARMACOLOGY: Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict…
Worked on BETATREX at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on BETATREX offers limited career growth due to its LOE-approaching status and minimal linked job postings; the product is in defensive, cost-management mode rather than expansion. Professionals joining this team should expect stabilization work, generic transition strategy, and eventual reassignment to higher-growth portfolio assets.